FDA-cleared profile

MEDO-Thyroid

MEDO DX Pte. Ltd. · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Views and quantifies thyroid ultrasound data with machine learning to aid thyroid-lobe analysis and identify, quantify, and document nodules in adults age 18 or older.

Clinical role
Software that uses machine learning to aid analysis of thyroid lobes and identification of thyroid nodules on ultrasound images; users view images, measure lobe and nodule volumes, and create and finalize examination reports, supporting the radiologist's workflow.
Images and patients
Ultrasound · Thyroid
Key limitation
Keep in mind: Adult images only and tested with high-frequency linear transducers on named Philips, GE, and Siemens systems; broader support is unknown.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Views and quantifies thyroid ultrasound data with machine learning to aid thyroid-lobe analysis and identify, quantify, and document nodules in adults age 18 or older.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Thyroid Input: DICOM ultrasound images including 2D, cine, and 3D single- or multi-frame images; landmarks and TI-RADS classification include user input.
  • Who uses it?Intended users: Qualified users, with workflow support for radiologists.
  • What does the software produce?Output: Thyroid-lobe and nodule volumes, distance and landmark tools, user-input TI-RADS score and classification, and examination reports.
  • What is its most important limitation?Key limitation: Adult images only and tested with high-frequency linear transducers on named Philips, GE, and Siemens systems; broader support is unknown.

Clinical takeaway. Clinical role: Views and quantifies thyroid ultrasound data with machine learning to aid thyroid-lobe analysis and identify, quantify, and document nodules in adults age 18 or older.

Evidence takeaway. Evidence from the reviewed source record: Software verification and validation reported lobe-volume ICC 0.972 and nodule-volume ICC 0.973 with stated confidence intervals; packet sample count was not stated.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Views and quantifies thyroid ultrasound data with machine learning to aid thyroid-lobe analysis and identify, quantify, and document nodules in adults age 18 or older.
  • Exact FDA submission
  • Checked 2026-09-15

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Software that uses machine learning to aid analysis of thyroid lobes and identification of thyroid nodules on ultrasound images; users view images, measure lobe and nodule volumes, and create and finalize examination reports, supporting the radiologist's workflow.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "It is designed to support the workflow by helping the radiologist to evaluate, quantify, and generate reports for thyroid ultrasound images." … "allows users to upload, browse, and view images, measure thyroid lobes and thyroid nodule volumes of single frame and multi-frame ultrasound images, as well as create and finalize examination reports.". Read from the exact FDA decision document on 2026-11-14.

Required input
DICOM ultrasound images including 2D, cine, and 3D single- or multi-frame images; landmarks and TI-RADS classification include user input.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet input scope.

Output and clinician action
Thyroid-lobe and nodule volumes, distance and landmark tools, user-input TI-RADS score and classification, and examination reports.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet output scope.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Qualified users, with workflow support for radiologists.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet user scope.

Limitations
Adult images only and tested with high-frequency linear transducers on named Philips, GE, and Siemens systems; broader support is unknown.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA limitation boundary.

Evidence summary
Software verification and validation reported lobe-volume ICC 0.972 and nodule-volume ICC 0.973 with stated confidence intervals; packet sample count was not stated.
  • Exact FDA submission
  • Checked 2026-09-15

Submission-reported technical result.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Software verification and validation reported lobe-volume ICC 0.972 and nodule-volume ICC 0.973 with stated confidence intervals; packet sample count was not stated.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

Submission-reported technical result.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

MEDO- Thyroid regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K203502
  • IndependenceIndependence not established

K203502

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K203502. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM ultrasound images including 2D, cine, and 3D single- or multi-frame images; landmarks and TI-RADS classification include user input.

    Scope: Exact FDA submission. FDA packet input scope.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-15 · FDA K203502: MEDO-Thyroid

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · MEDO- Thyroid model card (K203502)

  3. AI processing

    Source context, not route validation: The exact FDA package describes MEDO-Thyroid as a cloud-based standalone software as a medical device (SaMD) for image-based assessment of thyroid ultrasound images. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "MEDO-Thyroid is a cloud-based standalone software as a medical device (SaMD) that helps qualified users with image-based assessment of thyroid ultrasound images". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K203502: MEDO-Thyroid

  4. Returned objects

    Source context, not route validation: Thyroid-lobe and nodule volumes, distance and landmark tools, user-input TI-RADS score and classification, and examination reports.

    Scope: Exact FDA submission. FDA packet output scope.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-15 · FDA K203502: MEDO-Thyroid

  5. Viewer/worklist/report

    Unresolved route: Thyroid-lobe and nodule volumes, distance and landmark tools, user-input TI-RADS score and classification, and examination reports.

    Scope: Exact FDA submission. FDA packet output scope.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-15 · FDA K203502: MEDO-Thyroid

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes MEDO-Thyroid as a cloud-based standalone software as a medical device (SaMD) for image-based assessment of thyroid ultrasound images. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "MEDO-Thyroid is a cloud-based standalone software as a medical device (SaMD) that helps qualified users with image-based assessment of thyroid ultrasound images". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for MEDO-Thyroid; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K203502
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA thyroid-ultrasound scope.

Anatomy
Thyroid
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA thyroid scope.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-04-23
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K203502 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K203502: MEDO-Thyroid

    U.S. Food and Drug Administration - Published 2021-04-23 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. MEDO- Thyroid model card (K203502)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K203502

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K203502 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K240036

PIUR tUS Infinity

PIUR Imaging GmbH

Authorized purpose: PIUR tUS Infinity supports a computer-aided thyroid ultrasound workflow that identifies thyroid lobes and margins, calculates volume, marks and quantifies nodules, and provides user-selected ACR TI-RADS parameters subject to user review and confirmation.

Modality
Ultrasound
Anatomy
Thyroid
Decision
2024-09-20
FDA-cleared K252237

EdgeFlow UW20

Edgecare, Inc.

Authorized purpose: EdgeFlow UW20 is a wearable ultrasound system for noninvasive periodic bladder-volume measurement in adults with BMI no greater than 30.

Modality
Ultrasound
Anatomy
Urinary bladder
Decision
2026-04-17

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history